DeepScribe has no current public SaaS price, and an Australian App Store listing does not prove local sales, support or compliance. Australian buyers also need evidence on data transfers, coding fit and contract terms. We publish this guide and include our product in the alternatives comparison. We apply the same criteria to every product: price transparency, Australian availability, integration depth, privacy evidence and the quality of independent user feedback.

DeepScribe pricing is supplied by quote

DeepScribe does not publish a current subscription price or a standard Australian plan. Its standard terms put the payment amount, usage limits, supplemental services and other commercial details in a signed Order Form.

The standard terms displayed on 25 August 2026 make several cost and commitment points clear:

• invoices are issued monthly in US dollars unless the Order Form says otherwise;
• fees are non-cancellable and non-refundable by default;
• configuration, implementation, integration and training can be supplemental services;
• customers remain responsible for their own EHR licence and related fees; and
• an Order Form renews for the same duration unless either party gives written notice at least 30 days before the end of the term.

The Order Form can change those defaults. A useful quote therefore needs more than a per-user number.

First-year contracted cost = licence unit × committed users × billed periods + implementation + integration and EHR charges + training and support + foreign exchange and applicable tax

A complete proposal defines the billable user, minimum seat commitment, included products, usage limits, EHR work, onboarding, support levels, renewal price and exit assistance. For an Australian clinic, it also states the invoicing currency, GST treatment and responsibility for foreign-exchange or bank charges.

What the AWS Marketplace listing does and does not show

DeepScribe's AWS Marketplace listing displayed 12-, 24- and 36-month contract options on 25 August 2026. It advertised savings of up to 50% for 24 months and up to 67% for 36 months, with users as the pricing dimension.

That AWS page is a separate procurement route. Its options should not be treated as universal DeepScribe contract terms or proof of an Australian offer. The public table's $0.001 line is a marketplace dimension, not a usable SaaS subscription price. A configured purchase is still required.

What DeepScribe includes

On 25 August 2026, DeepScribe positioned its AI medical scribe for oncology and other complex specialties. Its product scope also included SmartPrep pre-visit intelligence, a Customization Studio and suggestions for E/M, HCC and ICD-10 coding. Its EHR integrations page presented native, two-way integrations with iKnowMed, OncoEMR and Epic. The Australian App Store listing also described schedule selection, recording, note review and EHR sign-off across iPhone, iPad and desktop.

Those capabilities create a stronger use case for a US oncology group than for an Australian general practice by default. An Australian buyer needs evidence for its own specialty, coding system, EHR configuration and governance requirements.

Australian availability has important gaps

The Australian App Store page proves that the iOS app can be downloaded in Australia. It displayed no ratings overview on 25 August 2026. Its app-privacy declaration was supplied by DeepScribe and was not verified by Apple. Download availability does not establish that DeepScribe sells, contracts, onboards or supports Australian healthcare organisations.

DeepScribe does not publicly document an Australian sales entity, local onboarding or support coverage, compliance with the Australian Privacy Principles (APPs), Australian data residency, an Information Security Registered Assessors Program (IRAP) assessment, or a product-specific Therapeutic Goods Administration (TGA) position. These are evidence gaps. They do not prove that a requirement cannot be met through a negotiated enterprise arrangement.

Data may be transferred to the United States

DeepScribe's privacy policy says personal data may be transferred from the user's location to DeepScribe and authorised third-party offices and servers in the United States. Its standard terms allow de-identified data to be retained, shared and used during and after the contract term for any legal purpose, including operating, analysing, improving or marketing the services.

For an organisation covered by the Privacy Act, APP 8 requires reasonable steps before disclosing personal information to an overseas recipient. The Australian entity can remain accountable for an overseas recipient's conduct in some circumstances. The OAIC's APP 8 guidance makes the due-diligence task practical: identify each recipient and location, assess protections, put enforceable privacy and security controls in the contract, and cover subprocessors, breach response, retention, deletion and access.

A US Health Insurance Portability and Accountability Act (HIPAA) commitment does not answer those Australian questions by itself.

US coding features do not establish Australian coding support

DeepScribe's E/M, HCC and ICD-10 features use US coding and reimbursement concepts. They do not establish support for:

• Medicare Benefits Schedule (MBS) item selection;
• ICD-10-AM diagnosis classification;
• Australian Classification of Health Interventions (ACHI); or
• Australian Coding Standards (ACS).

The MBS is Australia's list of Medicare-subsidised services. IHACPA maintains the distinct ICD-10-AM, ACHI and ACS system used for admitted patient care. Any Australian coding capability needs to name the local classification, edition, care setting and update process. A clinician or qualified coder still needs to confirm that the documentation and claimed service meet the applicable requirements.

TGA status depends on intended purpose

The TGA assesses software according to its intended purpose. Its digital scribe guidance distinguishes transcription and summarisation from functions that influence diagnosis, treatment or other clinical decisions. No public official source establishes DeepScribe's product-specific TGA status for an Australian configuration. The configured intended use, including any coding or clinical insight feature, needs a documented regulatory position.

What independent DeepScribe reviews show

The available review evidence is positive overall, with small samples and limited Australian relevance. The sources below measure different populations, so their review counts should remain separate.

What reviewers praise

Across the G2 reviews, clinicians commonly describe less charting, more attention for patients and responsive support. Several say they value starting from a generated note rather than a blank record. Some also report that direct integration reduces clicks and helps them finish documentation earlier.

The GetApp reviews similarly include praise for onboarding, support and completing notes after a high-volume clinic. These are self-reported experiences. They do not establish an average time saving or a result for an Australian practice.

Recurring concerns

The same G2 review set includes recurring concerns about inaccurate or incomplete content, information placed in the wrong note section, inconsistent detail and editing time. Historical reviews also mention an unavailable Intergy interface, lost transcriptions during an outage and difficulty distinguishing speakers. Product changes since those 2023 and 2024 submissions may have addressed some issues.

On GetApp, one January 2022 review reported that full functionality was unavailable on mobile devices. A June 2025 review criticised the price and automatic renewal after missing a 30-day cancellation window. Those individual accounts are useful contract and pilot prompts. They are not current proof that every deployment has the same mobile limitation or commercial terms.

How to use the ratings

Ratings suggest priorities for a local pilot. They cannot replace one because the samples are small, mostly older and not Australian. Useful pilot measures include:

• unsupported content, omissions and contradictions;
• information placed in the correct note section;
• editing and chart-close time;
• performance across accents, telehealth, multiple speakers and specialty terminology;
• the exact EHR launch, patient-context and write-back workflow; and
• support response when a note or integration fails.

Clinical responsibility remains with the clinician

Australian professional obligations apply whichever AI scribe a practice selects. Ahpra's AI guidance requires practitioners to involve patients when an AI tool needs their personal information, protect privacy and maintain professional judgement. The RACGP's AI scribe guidance says practices should obtain the consent appropriate to the workflow and jurisdiction, document it, and carefully check every generated note for false positives, false negatives and missing information.

DeepScribe's standard terms put responsibility for required notices and consents on the customer. They also require the customer to confirm the accuracy and reliability of recordings and state that the service does not make medical, diagnostic, treatment, coding or billing decisions.

In practice, that means:

1. give the patient an appropriate notice and obtain and record any consent required before capture;
2. review and correct every draft before it enters the patient record;
3. add relevant findings and context that were not spoken during the consultation; and
4. treat clinical and coding suggestions as prompts for professional review, never as independent advice.

Australian alternatives to compare

The most useful alternative is the one that fits the clinic's record system, document types, privacy requirements and implementation capacity. The comparison below applies those neutral criteria to three products with clear Australian-facing evidence.

Our current Australian price display needs confirmation

On 25 August 2026, our current Australian pricing page displayed Pro at $160 per month, with $1,920 billed annually, and $240 on the monthly-billing view. The live legacy Australian pricing page displayed $200 per user per month billed annually and $300 per user per month billed monthly. Neither page visibly labelled the currency or GST treatment. Those public pages conflict, so we cannot present a settled Lyrebird price.

Our Australian clinical notes and integrations pages provide the stronger basis for judging workflow fit. The same standard applies to every vendor: the live product needs to match the practice's consult types and exact record system before commercial terms are compared.

Questions to resolve before choosing DeepScribe

For an Australian clinic, a complete DeepScribe proposal should answer all of these in writing:

• Which Australian entity contracts for the service, and which team provides onboarding and support?
• What is the invoice currency, GST treatment, minimum commitment and renewal process?
• Which data types go to which countries, subprocessors and systems, and under what APP 8 controls?
• Is Australian data residency available, and is there relevant IRAP or independent security evidence?
• What is the TGA position for the configured intended purpose?
• Which Australian EHR, PMS and hospital integrations are live, and what does each one read and write?
• Does any coding function support MBS, ICD-10-AM, ACHI or ACS, and who validates the output?
• What pilot measures, acceptance criteria and exit rights apply before the full contract starts?

DeepScribe has credible positive review signals and a focused specialty product. Its public evidence still leaves material Australian questions unanswered. Local availability, privacy controls, integration behaviour and coding fit should carry as much weight as the headline review score.

For teams that want to evaluate an Australian clinical documentation workflow before entering an enterprise procurement process, we offer a free starting point.

Start for free